Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis

被引：1
|
作者：
James R. Spalding
Joel Hay
机构：
[1] Astellas Pharma US,Department of Pharmaceutical Economics and Policy
[2] School of Pharmacy,undefined
[3] University of Southern California,undefined
来源：
PharmacoEconomics | 2006年 / 24卷
关键词：
Rheumatoid Arthritis; Methotrexate; Infliximab; Etanercept; Adalimumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1221 / 1232
页数：11
相关论文
共 50 条
  • [41] Effectiveness and safety of the treatment with tumour necrosis factor a antagonists in rheumatoid arthritis patients
    Mendoza, MA
    Aznárez, HN
    Hernández, MJR
    Ruiz, FJM
    [J]. MEDICINA CLINICA, 2005, 125 (01): : 35 - 36
  • [42] Tumour necrosis factor blockade in rheumatoid arthritis
    Breedveld, FC
    [J]. CLINICAL MEDICINE, 2001, 1 (02) : 107 - 109
  • [43] Weight gain with tumour necrosis factor-α inhibitors
    Stamp, L
    Cross, N
    O'Donnell, J
    [J]. INTERNAL MEDICINE JOURNAL, 2005, 35 (04) : 267 - 267
  • [44] Comparative Long-Term Effectiveness of Switching to Another Tumour Necrosis Factor Antagonists, Tocilizumab or Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to a First-Line TNF Inhibitor
    Faria, Daniela Santos
    Eusebio, Monica
    Silva, Ioana Leite
    Rodrigues, Joana Ramos
    Neves, Joana Sousa
    Duarte, Ana Catarina
    Lopes, Carina
    Valido, Ana
    Dinis, Joana
    Freitas, Joao
    Santiago, Mariana
    Ferreira, Raquel
    Ganhao, Sara
    Miranda, Luis Cunha
    Peixoto, Daniela
    Teixeira, Filipa
    Alcino, Sergio
    Afonso, Carmo
    Costa, Jose Tavares
    Santos, Maria Jose
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [45] Predictors of Treatment Initiation with Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatoid Arthritis
    Desai, Rishi J.
    Rao, Jaya K.
    Hansen, Richard A.
    Fang, Gang
    Maciejewski, Matthew L.
    Farley, Joel F.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2014, 20 (11): : 1110 - 1120
  • [46] First-line treatments for rheumatoid arthritis
    Thorley, Jennifer
    [J]. LANCET RHEUMATOLOGY, 2023, 5 (09): : E507 - E507
  • [47] First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study
    da SilvaI, Michael Ruberson Ribeiro
    dos Santos, Jessica Barreto Ribeiro
    Kakehasi, Adriana Maria
    Almeida, Alessandra Maciel
    Pimenta, Pedro Ricardo Komel
    Alvares-Teodoro, Juliana
    Acurcio, Francisco de Assis
    [J]. SAO PAULO MEDICAL JOURNAL, 2022, 140 (06): : 787 - 797
  • [48] Tumour Necrosis Factor-α Inhibition Improves Stroke Outcome in a Mouse Model of Rheumatoid Arthritis
    Bonetti, N. R.
    Diaz-Canestro, C.
    Liberale, L.
    Crucet, M.
    Akhmedov, A.
    Merlini, M.
    Reiner, M. F.
    Gobbato, S.
    Stivala, S.
    Kollias, G.
    Ruschitzka, F.
    Luescher, T. F.
    Beer, J. H.
    Camici, G. G.
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [49] Tumour Necrosis Factor-α Antagonists in the Management of Rheumatoid Arthritis in the Elderly A Review of Their Efficacy and Safety
    Radovits, Beata J.
    Kievit, Wietske
    Laan, Roland F. J. M.
    [J]. DRUGS & AGING, 2009, 26 (08) : 647 - 664
  • [50] Tumour Necrosis Factor-α Antagonists in the Management of Rheumatoid Arthritis in the ElderlyA Review of Their Efficacy and Safety
    Beáta J. Radovits
    Wietske Kievit
    Roland F. J. M. Laan
    [J]. Drugs & Aging, 2009, 26 : 647 - 664
12345